General Biologicals

General Biologicals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of General Biologicals (4117.TWO) as of Oct 31, 2026 is -65.00 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 741.92 % — a change of -108.76% (lower).

FCF Conversion

-65.00 %

YoY

-108.76%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of General Biologicals is 2025 -65.00 % . FCF Conversion Rate (FCF/EBITDA) of General Biologicals was 2024 741.92 % . It decreases by -108.76% lower compared to the previous year.

The General Biologicals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
75.11 TWD
Jan 1, 2019
7.43 TWD
Jan 1, 2020
33.49 TWD
Jan 1, 2021
-194.49 TWD
Jan 1, 2022
44.37 TWD
Jan 1, 2023
100.25 TWD
Jan 1, 2024
741.92 TWD
Jan 1, 2025
-65.00 TWD
The General Biologicals FCF Conversion history
YEARFCF ConversionYoY
-65.00 %-108.76%
741.92 %+640.06%
100.25 %+125.97%
44.37 %-122.81%
-194.49 %-680.70%
33.49 %+350.78%
7.43 %-90.11%
75.11 %-4.80%
78.90 %-11.58%
89.23 %+30.82%
68.21 %-38.08%
110.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

General Biologicals Stock analysis

What does General Biologicals do? General Biologicals Corp., headquartered in Baoshan, Hsinchu, Taiwan, operates in the Health Care sector, specifically within the Biotechnology industry. The company engages in research, development, manufacturing, and trading of diagnostics, pharmaceuticals, and medical supplies. Its main products include detection reagents, biological protein new drugs, P113, and medical supplies, distributed domestically and internationally. Listed on 4 July 2002, the company employs 63 people. General Biologicals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about General Biologicals stock

FCF Conversion Rate (FCF/EBITDA) of General Biologicals is -65.00 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of General Biologicals changed from 741.92 % to -65.00 %, representing a -108.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) General Biologicals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s General Biologicals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — General Biologicals

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — General Biologicals